ATE265860T1 - Impstoff zur behandlung von atherosclerosis - Google Patents

Impstoff zur behandlung von atherosclerosis

Info

Publication number
ATE265860T1
ATE265860T1 AT01919363T AT01919363T ATE265860T1 AT E265860 T1 ATE265860 T1 AT E265860T1 AT 01919363 T AT01919363 T AT 01919363T AT 01919363 T AT01919363 T AT 01919363T AT E265860 T1 ATE265860 T1 AT E265860T1
Authority
AT
Austria
Prior art keywords
atherosclerosis
vaccine
treatment
Prior art date
Application number
AT01919363T
Other languages
English (en)
Inventor
Jean-Charles Fruchart
Philippe Monteyne
Remi Palmantier
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005240A external-priority patent/GB0005240D0/en
Priority claimed from GB0022005A external-priority patent/GB0022005D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE265860T1 publication Critical patent/ATE265860T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01919363T 2000-03-03 2001-03-01 Impstoff zur behandlung von atherosclerosis ATE265860T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005240A GB0005240D0 (en) 2000-03-03 2000-03-03 Vaccine
GB0022005A GB0022005D0 (en) 2000-09-07 2000-09-07 Vaccine
PCT/EP2001/002326 WO2001064008A2 (en) 2000-03-03 2001-03-01 Vaccine for the treatment of artherosclerosis

Publications (1)

Publication Number Publication Date
ATE265860T1 true ATE265860T1 (de) 2004-05-15

Family

ID=26243793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01919363T ATE265860T1 (de) 2000-03-03 2001-03-01 Impstoff zur behandlung von atherosclerosis

Country Status (19)

Country Link
US (1) US20030165503A1 (de)
EP (1) EP1267908B1 (de)
JP (1) JP2003525883A (de)
KR (1) KR20020079983A (de)
CN (1) CN1418106A (de)
AR (1) AR027591A1 (de)
AT (1) ATE265860T1 (de)
AU (1) AU2001246493A1 (de)
BR (1) BR0108924A (de)
CA (1) CA2401755A1 (de)
CZ (1) CZ20022971A3 (de)
DE (1) DE60103137T2 (de)
ES (1) ES2219517T3 (de)
HU (1) HUP0300099A3 (de)
IL (1) IL151355A0 (de)
MX (1) MXPA02008616A (de)
NO (1) NO20024172L (de)
PL (1) PL365424A1 (de)
WO (1) WO2001064008A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
CZ20021571A3 (cs) * 2000-09-04 2002-09-11 Hyo-Joon Kim Mimetické peptidy k epitopu apolipoproteinu B-110, jejich konkatemer a modifikované peptidy, a vakcinační přípravek, který je obsahuje
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2002098919A2 (en) * 2001-06-05 2002-12-12 Genfit Method for apo ciii measurement in apob and non apob containing particles
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
GB0305794D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
EP1872138A1 (de) * 2005-04-11 2008-01-02 AstraZeneca AB Verfahren und kit zur diagnose von typ-2-diabetes, stoffwechselsyndrom, subklinischer atherosklerose, myokardinfarkt, schlaganfall oder klinischer anzeichen von diabetes
WO2009152493A2 (en) * 2008-06-13 2009-12-17 The General Hospital Corporation Use of apolipoproteins to decrease inflammation
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
US9783600B2 (en) 2013-02-25 2017-10-10 Imbp Holding, Llc Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
US11130798B2 (en) * 2015-05-19 2021-09-28 La Jolla Institute For Allergy And Immunology Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
CN106810606A (zh) * 2015-11-27 2017-06-09 西藏自治区人民医院 一种载脂蛋白c-ⅲ抗原多肽及其多克隆抗体的制备与应用
WO2017205454A1 (en) * 2016-05-24 2017-11-30 Bryce Chackerian Immunogens, compositions, and methods for treating dyslipidemia
EP3481864A1 (de) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
CN106519007B (zh) * 2016-12-12 2019-07-02 王家祥 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN110590937A (zh) * 2018-06-13 2019-12-20 杨宝田 一种人血载脂蛋白a1制品的制备方法及应用
MX2023000904A (es) 2020-07-22 2023-02-22 3H Bio Co Ltd Un peptido utilizado para agentes inmunoterapeuticos.
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
EP4402263A2 (de) 2021-09-14 2024-07-24 Argonaute Rna Limited Behandlung von herz-kreislauf-erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6522486A (en) * 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
IL104015A0 (en) * 1992-12-07 1993-05-13 Doina International Ltd P Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
WO1998007751A1 (en) * 1996-08-23 1998-02-26 Pharmacia & Upjohn Ab A process for purifying apolipoprotein a or apolipoprotein e from human plasma
US6492185B1 (en) * 1998-01-16 2002-12-10 Abbott Laboratories Immunoassay for detection of very low density lipoprotein and antibodies useful therefor
FR2776388B1 (fr) * 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique

Also Published As

Publication number Publication date
AR027591A1 (es) 2003-04-02
WO2001064008A2 (en) 2001-09-07
CN1418106A (zh) 2003-05-14
KR20020079983A (ko) 2002-10-21
ES2219517T3 (es) 2004-12-01
NO20024172D0 (no) 2002-09-02
PL365424A1 (en) 2005-01-10
BR0108924A (pt) 2003-04-29
DE60103137T2 (de) 2005-05-25
HUP0300099A3 (en) 2004-10-28
JP2003525883A (ja) 2003-09-02
IL151355A0 (en) 2003-04-10
US20030165503A1 (en) 2003-09-04
WO2001064008A3 (en) 2002-02-14
EP1267908A1 (de) 2003-01-02
DE60103137D1 (de) 2004-06-09
AU2001246493A1 (en) 2001-09-12
CA2401755A1 (en) 2001-09-07
HUP0300099A2 (en) 2003-05-28
CZ20022971A3 (cs) 2003-02-12
NO20024172L (no) 2002-11-01
MXPA02008616A (es) 2003-02-24
EP1267908B1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60138129D1 (de) Apparat zur behandlung von zähnen
EP1324780A4 (de) Methoden zur behandlung von herzarrhythmie
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60103685D1 (de) Behandlung von Poriomania

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties